Stereotactic Body Radiation Therapy (SBRT) Efficiency and Toxicity in Liver Cancer
Condition(s) studied
Investigational drug(s) / intervention(s)
SBRT: 3 sessions at least, up to 6. Neither specifc device is imposed.
Study summary
Intervention research involving the human person, phase II, prospective, multicentric, non-randomized and multi-cohort study. The eligibility criteria are broad, on purpose, so every patient, able to be treated by SBRT and unable to participate in another trial (non eligible patient or non included centers), can be included in this national study, in a prospective way.
Eligibility
Primary outcome measure(s)
- SBRT efficiency in term of L-PFS for patient who are to be treated with SBRT in patients with primitive hepatic tumor of hepatic metastatis — From baseline to 36 months following up.
Local progression-free survival (L-PFS) thanks to Kaplan-Meier method from registration date to date of local progressive disease.
Trial sites (7)
| Facility | City | Region | Status |
|---|---|---|---|
| Centre Oscar Lambret | Lille | Nord | |
| Centre Léonard de Vinci | Dechy | France | |
| Institut Régional du Cancer de Montpellier | Montpellier | France | |
| Institut de Cancérologie Paris Nord | Sarcelles | France | |
| Centre Paul Strauss | Strasbourg | France | |
| Institut de Cancérologie de Lorraine | Vandœuvre-lès-Nancy | France | |
| Institut Gustave Roussy | Villejuif | France |
More Centre Oscar Lambret trials in France
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT03408665 on ClinicalTrials.gov ↗ ← All trials in France